1-7 of 7
Ann Jakubowski, MD
Close
Sort by
Journal Articles

Early Immune Recovery Predicts Overall and Disease-Free Survival After Allogeneic Hematopoietic Stem Cell Transplantation.

Jenna D. Goldberg, MD, Junting Zheng, MA, Juliet Barker, MBBS, Farid Boulad, MD, H.R. Castro-Malaspina, MD, Katharine C Hsu, MD, PhD, Ann Jakubowski, MD, PhD, Nancy Kernan, MD, Richard J O'Reilly,, MD, Esperanza Papadopoulos, MD, Susan Prockop, MD, Andromachi Scaradavou, MD, Marcel van den Brink, MD, PhD, James Young, MD, Glenn Heller, PhD, Miguel-Angel Perales, MD
Journal: Blood
Blood (2009) 114 (22): 2222.
https://doi.org/10.1182/blood.V114.22.2222.2222
Published: 2009
Journal Articles

Phase II Trial of a Chemotherapy-Only Regimen of Busulfan, Melphalan, Fludarabine and R-ATG Followed by Allogeneic T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplants (HSCT) for the Treatment of Myeloid Malignancies.

Farid Boulad, MD, Ann Jakubowski, MD, Esperanza Papadopoulos, MD, Katharine C. Hsu, MD, Miguel Angel Perales, MD, Marcel van den Brink, MD, James W. Young, MD, Michelle Chiu, Nancy A. Kernan, MD, Susan E. Prockop, MD, Andromachi Scaradavou, MD, Trudy N. Small, MD, Hugo Castro-Malaspina, MD, Richard J. O’Reilly, MD
Journal: Blood
Blood (2007) 110 (11): 2991.
https://doi.org/10.1182/blood.V110.11.2991.2991
Published: 2007
Journal Articles

Pilot Trial of Rituximab for the Prevention of Epstein Barr Virus B Cell Lymphoproliferative Disorder (EBV-LPD) Following T Cell Depleted (TCD) Unrelated or HLA-Mismatched Related Hematopoietic Stem Cell Transplantation.

Trudy N. Small, MD, Nancy A. Kernan, MD, Ann Jakubowski, MD, PhD, James W. Young, MD, Susan Prockop, MD, Miguel-Angel Perales, MD, Richard J. O’Reilly, MD, Esperanza B. Papadopoulos, MD
Journal: Blood
Blood (2006) 108 (11): 2922.
https://doi.org/10.1182/blood.V108.11.2922.2922
Published: 2006
Journal Articles

PCR Screening for Epstein-Barr Virus-Related Lymphoproliferative Disease (EBV-LPD) among Allogeneic Stem Cell Transplant (AlloSCT) Recipients: The Importance of T Cell Depletion.

Giannina Garces Ambrossi, Ann Jakubowski, MD, PhD, Carrie Brennan, Timothy E. Kiehn, PhD, David M. Weinstock, MD
Journal: Blood
Blood (2005) 106 (11): 3234.
https://doi.org/10.1182/blood.V106.11.3234.3234
Published: 2005
Journal Articles

Response to Immunizations Following Allogeneic HCT with Adjuvant Rituximab Therapy.

Mary Pao, MD, PhD, Esperanza B. Papadopoulos, MD, Farid Boulad, MD, Hugo Castro-Malaspina, MD, Ann Jakubowski, MD, PhD, Nancy A. Kernan, MD, Miguel Perales, MD, Susan Prockop, MD, Ruth Ford, RN, James W. Young, MD, Richard J. O’Reilly, MD, Trudy N. Small, MD
Journal: Blood
Blood (2005) 106 (11): 3242.
https://doi.org/10.1182/blood.V106.11.3242.3242
Published: 2005
Journal Articles

Response to Hepatitis B Vaccination Following Allogeneic Hematopoietic Cell Transplantation (HCT).

Trudy N. Small, MD, Esperanza B. Papadopoulos, MD, Farid Boulad, MD, Hugo Castro-Malaspina, MD, Ann Jakubowski, MD, PhD, Nancy A. Kernan, MD, Miguel Perales, MD, Susan Prockop, MD, James W. Young, MD, Richard J. O’Reilly, MD, Dana Jaffe, MPH
Journal: Blood
Blood (2005) 106 (11): 83.
https://doi.org/10.1182/blood.V106.11.83.83
Published: 2005
Journal Articles

A Phase II Trial of Busulfan, Melphalan, and Fludarabine followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants from HLA-Identical, or HLA-Non Identical Related or Unrelated Donors for the Treatment of Advanced Hematopoietic Malignancies.

Farid Boulad, MD, Ann Jakubowski, MD, Hugo Castro-Malaspina, MD, Katharine C. Hsu, MD, Nancy A. Kernan, MD, Esperanza B. Papadopoulos, MD, Miguel A. Perales, MD, Susan E. Prockop, MD, Trudy N. Small, MD, Marcel R.M. van den Brink, MD, James W. Young, MD, Michelle Ro, Nancy Collins, PhD, Richard J. O’Reilly, MD
Journal: Blood
Blood (2004) 104 (11): 1822.
https://doi.org/10.1182/blood.V104.11.1822.1822
Published: 2004